Artikkelit - Selaus asiasanan mukaan "immunogenicity"
Viitteet 1-5 / 5
-
2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines ‘Scientific’? : Part 1 – LCMS: small molecules, peptides and small molecule biomarkers
Bioanalysis : 22 (Future Science, 17.11.2017)The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical ... -
2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies’ inputs
Bioanalysis : 23 (Future Science, 05.12.2017)The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical ... -
2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 3 – LBA: immunogenicity, biomarkers and PK assays
Bioanalysis : 9 (Future Science, 05.12.2017)The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical ... -
Biosimilar regulation in the EU
Expert review of clinical pharmacology : 5 (Taylor & Francis, 2015) -
Interchangeability of Biosimilars : A European Perspective
BioDrugs : 2 (Springer International Publishing, 01.04.2017)Many of the best-selling ‘blockbuster’ biological medicinal products are, or will soon be, facing competition from similar biological medicinal products (biosimilars) in the EU. Biosimilarity is based on the comparability ...
